Oxurion & Bicycle Therapeutics declare full enrollment for DME study
Category: #health  By Nikita Chaurasia  Date: 2019-04-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Oxurion & Bicycle Therapeutics declare full enrollment for DME study

Bicycle Therapeutics, a biotech firm pioneering a new therapeutic class based on its patented bicyclic peptide or Bicycle® platform, and Oxurion have recently declared complete registration of Oxurion’s Phase I clinical trial planned to assess the safety of THR-149’s single injection. The injection essentially is a new Bicycle-based plasma kallikrein suppressor.

According to a press release by the Bicycle Therapeutics, the agreement states that Oxurion has exclusive authority to conduct clinical and preclinical development, as well as commercialization of a designated medicine candidate. In return, Bicycle would attain milestone payments for development and royalties on sales of products resulting from the association.

Bicycle provides a differentiated method to a variety of debilitating ailments, and the company is pleased to view the growth Oxurion has attained in successfully finishing the registration of the Phase I study of the first Bicycle-based therapeutic, stated Kevin Lee, Ph.D., CEO Bicycle Therapeutics.

THR-149, in consort with Bicycle-owned BT1718, Bicycle Toxin Conjugate for oncology, represents the first of many initiatives the firm is proceeding with to bring this exceptional therapeutic modality to patients with significant unfulfilled medical needs, Lee added.

Patrik De Haes, M.D. & CEO of Oxurion, reportedly stated that patients suffering from diabetic macular edema have higher levels of PKal. Our aim in the current Phase I clinical trial is to assess the safety of a single THR-149 intravitreal injection, a new Bicycle-based PKal suppressor, in patients having visual impairment because of diabetic macular edema, Haes stated. Enrolling subjects is the first step to assessing whether we can constrain PKal with Bicycle’s new bicyclic peptides, he added.

For the record, Bicycle Therapeutics is a clinical-phase biopharmaceutical firm developing a new class of pills, termed as Bicycles, for illnesses that are underserved by currently available therapeutics. It was founded in 2009, resulting from an innovative science performed by Professor Christian Heinis and Sir Greg Winter.

Source Credits: https://www.apnews.com/Business%20Wire/2aec99859114480da690c30619ccc460

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Styrene Butadiene Latex Market to register extensive growth via paper processing sector
Styrene Butadiene Latex Market to register extensive growth via paper processing sector
By Nikita Chaurasia

The paper processing sector stands as one of the major application arenas of styrene butadiene latex market. The product is extensively used for paper coating in magazines, newspapers, flyers, catalogues and paper food cartons, given that it enhances...

Liquid Nitrogen Market to witness heavy growth prospects via oil & gas industry over 2019-2025
Liquid Nitrogen Market to witness heavy growth prospects via oil & gas industry over 2019-2025
By Nikita Chaurasia

For the liquid nitrogen market, the oil & gas industry is one of the most prominent end-use spaces. With a commendable boost in shale oil and gas sectors in recent years and spike in hydraulic fracturing, enhanced oil recovery, which greatly invo...

Muconic Acid Market Size will show exponential growth via construction industries over 2019 – 2024
Muconic Acid Market Size will show exponential growth via construction industries over 2019 – 2024
By Nikita Chaurasia

The size of Muconic Acid Market was anticipated as 37 million in the year 2019 and is predicted to touch 60 million till 2024, rising with a CAGR of 6.5% between the years 2019 to 2024 as per the research done by Global Market Insights, Inc. Muconic...